Share on StockTwits

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have been given a consensus rating of “Hold” by the sixteen brokerages that are covering the company, StockRatingsNetwork.com reports. Four equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.14.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated an “underperform” rating on shares of Auxilium Pharmaceuticals in a research note on Wednesday. They now have a $16.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of Auxilium Pharmaceuticals from $32.00 to $28.00 in a research note on Friday, August 8th. They now have an “outperform” rating on the stock. Finally, analysts at Aegis cut their price target on shares of Auxilium Pharmaceuticals to $34.00 in a research note on Thursday, August 7th. They noted that the move was a valuation call.

Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 17.35 on Wednesday. Auxilium Pharmaceuticals has a 1-year low of $16.36 and a 1-year high of $32.89. The stock’s 50-day moving average is $19.34 and its 200-day moving average is $23.67. The company’s market cap is $872.0 million.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last released its earnings data on Thursday, August 7th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.64 by $2.08. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million. During the same quarter in the prior year, the company posted $0.22 earnings per share. The company’s quarterly revenue was down 17.4% on a year-over-year basis. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.41 earnings per share for the current fiscal year.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.